1129403-56-0

Basic information

• Product Name: BBI-503(BB-503)
• Synonyms: BBI-503(BB-503);BBI-503;Amcasertib (BBI503);QDWKGEFGLQMDAM-UHFFFAOYSA-N
• CAS NO: 1129403-56-0
• Molecular Formula: C₃₁H₃₃N₅O₂S
• Molecular Weight: 539.69102
• EINECS: -0
• Mol File: 1129403-56-0.mol

Chemical Properties

• Appearance: /
• Density: 1.246±0.06 g/cm3(Predicted)
• PKA: 11.99±0.20(Predicted)
• CAS DataBase Reference: BBI-503(BB-503)(CAS DataBase Reference)
• NIST Chemistry Reference: BBI-503(BB-503)(1129403-56-0)
• EPA Substance Registry System: BBI-503(BB-503)(1129403-56-0)

Safety Data

• Hazardous Substances Data: 1129403-56-0(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
BBI-503 (BB-503) is used as an anti-cancer agent for its ability to target and inhibit the STAT3 signaling pathway in cancer stem cells, thereby preventing tumor growth and recurrence. In preclinical studies, it has demonstrated promising anti-cancer activity against a variety of solid tumors, including breast, lung, and colon cancer.
Used in Clinical Trials:
BBI-503 (BB-503) is currently being investigated in clinical trials for the treatment of advanced solid tumors. It is being evaluated both as a standalone therapy and in combination with other anti-cancer agents to enhance the overall effectiveness of cancer treatment.
Used in Drug Development:
As a small molecule inhibitor, BBI-503 (BB-503) serves as a valuable asset in the development of targeted cancer therapies. Its ability to specifically target cancer stem cells and inhibit the STAT3 signaling pathway makes it a promising candidate for further research and development in the field of oncology.

Upstream product

• 1129403-60-6 C₁₇H₁₂N₂OS*ClH 
• 2227-79-4 benzenecarbothioamide 
• 65435-04-3 5-chloroacetylindolin-2-one 
• 1129403-61-7 C₂₅H₁₉N₃O₃S 
• 100-36-7 N,N-diethylethylenediamine 

Relevant articles and documents

Treatment of non-alcoholic fatty liver disease

The invention provides novel methods of treating or preventing nonalcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH) in a mammal including a human.

Treatment of obesity

The invention provides novel methods of treating or preventing obesity or overweight and closely associated comorbidities therewith in a mammalian subject including human.

HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE

Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.

COMPOSITIONS OF KINASE INHIBITORS AND THEIR USE FOR TREATMENT OF CANCER AND OTHER DISEASES RELATED TO KINASES

The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to